GSEP
JBIO

Golden State Equity Partners’s Jade Biosciences JBIO Stock Holding History

Golden State Equity Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$246K Buy
311
+10
+3% +$5.1K 0.06% 314
2023
Q3 		$143K Hold
301
– – 0.04% 325
2023
Q2 		$181K Hold
301
– – 0.05% 350
2023
Q1 		$212K Buy
+301
New +$250K 0.11% 195
2022
Q1 		$385K Buy
599
+144
+32% +$55.9K 0.19% 128
2021
Q4 		$188K Buy
+455
New +$230K 0.1% 163

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Golden State Equity Partners's JBIO Position: Q4 2023 in Review

Golden State Equity Partners increased its Jade Biosciences (JBIO) stake by 3.3% in Q4 2023, buying an estimated $5.1K and bringing the position to 311 shares worth $246K. The position accounts for 0.06% of the portfolio, ranked #314.

Golden State Equity Partners first reported a position in JBIO in Q4 2021 and has held it in 6 quarters since. The position peaked at $385K in Q1 2022. 64 funds tracked by Wall St. Rank hold JBIO as of Q4 2023.

  • Golden State Equity Partners held 311 shares of Jade Biosciences worth $246K as of Q4 2023.
  • Golden State Equity Partners bought 10 Jade Biosciences shares in Q4 2023, an estimated $5.1K.
  • Jade Biosciences made up 0.06% of Golden State Equity Partners's portfolio in Q4 2023, its #314 holding.
  • Golden State Equity Partners first reported a position in Jade Biosciences in Q4 2021 and has held it in 6 quarters since.
  • Golden State Equity Partners's Jade Biosciences position peaked at $385K in Q1 2022.
  • 64 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2023.

Based on Golden State Equity Partners's 13F filing for Q4 2023, filed 2 Feb 2024.